← Back to Search

ARD-101 for Obesity

Phase 2

Waitlist Available

Research Sponsored by Aardvark Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up screening, days 1, 15, and 28

Awards & highlights

Study Summary

This trial will test a new drug for people who had weight-loss surgery. The drug is taken twice daily, and the trial will evaluate how well it works and if it is safe.

Eligible Conditions

Post-Gastric Bypass Surgery
Obesity

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ run-in visit (baseline)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~run-in visit (baseline)

This trial's timeline: 3 weeks for screening, Varies for treatment, and run-in visit (baseline) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Relative Change in Body Weight (%)

Secondary outcome measures

Change in Blood Lipid Concentrations

Change in Hemoglobin A1c

Waist Circumference

+1 more

Other outcome measures

Area under the Curve (AUC) of Serum Level of C-peptide (ng/mL) during MMTT

Area under the Curve (AUC) of Serum Level of Glucose (mg/dL) during MMTT

Area under the Curve (AUC) of Serum Level of Insulin (uIU/mL) during MMTT

+31 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: ARD-101Experimental Treatment1 Intervention

Dose 200 mg of ARD-101, twice daily for 28 days

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ARD-101

2021

Completed Phase 2

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Aardvark Therapeutics, Inc.Lead Sponsor

3 Previous Clinical Trials

50 Total Patients Enrolled

1 Trials studying Obesity

20 Patients Enrolled for Obesity

University of California, San DiegoOTHER

1,120 Previous Clinical Trials

1,521,395 Total Patients Enrolled

52 Trials studying Obesity

7,470 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the application window for this trial still available?

"Affirmative. According to the information displayed on clinicaltrials.gov, this medical trial is actively seeking participants and has been since March 1st 2022. The last update was made October 18th of that same year and so far 30 people have enrolled from a single site."

Answered by AI

Does the demographic of 65+ apply to this research investigation?

"This medical study has established an age limit between 18 and 75 years old for participants, as specified in the inclusion criteria."

Answered by AI

What are the criteria to be a participant in this research trial?

"This trial is currently recruiting 30 individuals with a BMI between 35-60 kg/m2 and ages ranging from 18 to 75. To be eligible, one must meet the following criteria: Male or female subjects aged 18-75 years old; they have undergone sleeve gastrectomy surgery at least 12 months ago and regained 20% of their nadir weight loss (defined as maximum preoperative weight - weight corresponding to a BMI of 25 kg/m2); serum creatinine, alkaline phosphatase, hepatic enzymes (aspartate aminotransferase, alanine aminotransferase) and"

Answered by AI

What is the total participant count for this experiment?

"Affirmative. Information on clinicaltrials.gov indicates that this research project is presently accepting enrolment, having been first posted on March 1st 2022 and most recently modified October 18th 2022. 30 individuals are sought after from a single site for the trial."

Answered by AI

Has the U.S. Food and Drug Administration given their stamp of approval for ARD-101?

"Our analysts at Power assigned ARD-101 a score of 2 on the safety scale as it is currently in its second trial phase, meaning there are some data backing up security but no evidence confirming efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery

2022. "Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05215847.